Form 4: Glycomimetics CEO Sells Shares
Insider Transaction (Form 4)
Joshua T Brumm, Chief Executive Officer and a Director of Glycomimetics Inc, sold 9,447 shares of common stock on September 16, 2026.
Summary
- Open-market sale: disposed of 1,610 Ordinary Shares at $17.90 ($28,819) on September 16, 2026; holds 279,602 after (Direct).
- Open-market sale: disposed of 7,837 Ordinary Shares at $16.71 ($130,956) on September 18, 2026; holds 271,765 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $159,775 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Joshua T Brumm — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-16 | Open-market sale | Ordinary Shares | 1,610 | $18 | $28.8K | 279,602 |
| 2026-09-18 | Open-market sale | Ordinary Shares | 7,837 | $17 | $131.0K | 271,765 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-16 | Open-market sale (1,610 shares) |
| 2026-09-18 | Open-market sale (7,837 shares) |
Keywords
insider transaction, Form 4, CBIO, CRESCENT BIOPHARMA, INC., bearish, Joshua T Brumm
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.